ClinicalTrials.Veeva

Menu

Clinical Evaluation of the FluidVision Accommodating Intraocular Lens (AIOL)

P

PowerVision

Status

Completed

Conditions

Aphakia

Treatments

Procedure: Cataract Surgery
Device: FluidVision AIOL

Study type

Interventional

Funder types

Industry

Identifiers

NCT02049567
AIOL-2009-1

Details and patient eligibility

About

The purpose of this study is to evaluate the safety and effectiveness of an investigational IOL.

Full description

Eligible subjects will receive the investigational IOL in one eye and be followed at 1 day, 1 week, 1 month, 3 months, 6 months, 12 months, 18 months, 24 months and 36 months post-operation.

Enrollment

170 patients

Sex

All

Ages

50+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Key Inclusion Criteria:

  • Eligible for primary intraocular lens implantation for the correction of aphakia following cataract extraction;
  • Best corrected distance visual acuity worse than 20/40 either with or without a glare source present (e.g. Brightness Acuity Tester);
  • Less than or equal to 1.0 diopter (D) of preoperative keratometric astigmatism;
  • Willing and able to comply with schedule for follow-up visits for 36 months after surgery.
  • Other protocol-defined inclusion criteria may apply.

Key Exclusion Criteria:

  • Systemic disease that could increase the operative risk or confound the outcome (e.g. autoimmune disease, diabetes);
  • Taking systemic medications that may confound the outcome or increase the risk to the subject;
  • Ocular conditions that may predispose for future complications;
  • Previous intraocular or corneal surgery that might confound the outcome of the investigation or increase the risk to the subject;
  • Pregnant, lactating during the course of the investigation, or with another condition associated with fluctuation of hormones that could lead to refractive changes;
  • Diagnosed degenerative visual disorders (e.g. macular degeneration or other retinal disorders) that are predicted to cause future best corrected visual acuity loss worse than 20/40.
  • Other protocol-defined exclusion criteria may apply.

Trial design

Primary purpose

Device Feasibility

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

170 participants in 1 patient group

FluidVision
Experimental group
Description:
FluidVision AIOL implanted in the capsular bag of the eye during cataract surgery
Treatment:
Procedure: Cataract Surgery
Device: FluidVision AIOL

Trial contacts and locations

8

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems